Developing Novel Immunotherapeutics for Acute Myeloid Leukemia
Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and the second most common pediatric leukemia. The goal of this funded project is to develop novel form of therapeutic agents for selective killing of AML cells through activating and redirecting cellular immunity. This will be achieved by exploiting a multidisciplinary approach to design, generate, and characterize the proposed therapeutic exosomes using cellular and animal models of AML. During the first year of the performance period, we rationally designed and analyzed multiple therapeutic fusion constructs and performed initial characterization of the physicochemical properties and biological activity for the resulting genetically engineered exosomes. While we continue the evaluation of the designed exosomes, we are designing and generating additional types of engineered exosomes for further analysis and characterization.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1114582
Entities
People
- Yong Zhang
Organizations
- University of Southern California